Gå ubegrenset med Magzter GOLD

Gå ubegrenset med Magzter GOLD

Få ubegrenset tilgang til over 9000 magasiner, aviser og premiumhistorier for bare

$149.99
 
$74.99/År

Prøve GULL - Gratis

80+ Trials Underway To Treat Covid-19

BioSpectrum Asia

|

April 2020

In just over 90 days of identification of a pneumonia of unknown cause, the novel coronavirus pandemic, which is raging around the world and posing a challenge for all countries and regions. As on April 2,2020 the number of confirmed COVID-19 cases worldwide has risen above 1 million, according to the new tally from Johns Hopkins University. Since the emergence of the novel coronavirus (COVID-19), biopharmaceutical companies across the world have stepped up their research efforts to develop vaccines and treatments in order to contain the virus. As of March 26, 2020, there are a number of therapeutics currently in clinical trials and more than 52 candidate vaccines are in preclinical evaluation for COVID-19 and 2 candidate vaccines are in clinical evaluation. Over 80 clinical trials are underway to test new and existing medicines across the globe.

- Narayan Kulkarni

80+ Trials Underway To Treat Covid-19

At the close of 2019, i.e. on December 31 the WHO China Country Office was informed of a pneumonia of unknown cause, detected in the city of Wuhan in Hubei province, China. According to the authorities, some patients were operating dealers or vendors in the Huanan Seafood market. After 7 days the Chinese authorities identified the virus that caused the pneumonia-like illness as a new type of coronavirus (called novel coronavirus or nCoV). The first death in China due to this nCoV was recorded on January 10 even as officials confirmed a case of the novel coronavirus out of China-in Thailand-on January 13. WHO noted that it was not unexpected that cases of the novel coronavirus would emerge outside of China and reinforced why WHO calls for active monitoring and preparedness in other countries. Then it was no looking back for this novel coronavirus as it spread to over 200 countries with a total of 1,002,159 people being diagnosed across the world, a death toll of 51,485 and recovery of more than 200,000 patients as shown by the regularly updated tally of the Johns Hopkins University’s Center for Systems Science and Engineering in the US as on April 2.

Disease outbreaks present a unique opportunity for research, but this can only happen if experts in different countries share information promptly. The decision by Chinese authorities to release the genetic sequence of the newly discovered beta coronavirus for researchers worldwide exemplifies the transparency needed to tackle unfolding public health emergencies. This helped the scientists to have vital genetic data that will help speed up the development of diagnostic tests, case detection and, potentially, a vaccine.

FLERE HISTORIER FRA BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Waters launches charge detection mass spectrometry technology

US-based Waters Corporation has unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterisation for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Chulalongkorn University launches Thailand's first master's programme in Nurse Anesthesia

The Faculty of Nursing, Chulalongkorn University, has officially launched the \"Master of Nursing Science Programme in Nurse Anesthesia\" - the first of its kind in Thailand.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

WHO strengthens coordination for NTD programmes and supply chain delivery

The World Health Organization (WHO), together with health ministries, pharmaceutical donours, implementing partners and technical support platforms, is strengthening coordination for neglected tropical disease (NTD) programmes and supply chain delivery, through three major back-to-back meetings in Geneva.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

All-in-one coronavirus vaccines to save millions in future pandemics

A new study reveals that vaccines designed to protect against a wide range of coronaviruses could dramatically reduce deaths and economic disruption and limit the need for lockdowns in the event of another global coronavirus pandemic.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

NTU in Singapore introduces Master of Science course in Chinese Medicine

From 2026, Nanyang Technological University (NTU) in Singapore will start offering a Master of Science in Chinese Medicine to develop highly skilled postgraduates with advanced expertise in both the theoretical foundations and practical applications of Chinese medicine.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

ProSpecBio launches Activin-A recombinant protein for brain injury research

Israel-based ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, has announced the launch of its latest product: CHO cell-derived recombinant Activin-A, now available for immediate delivery worldwide.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

PAHO publishes guide for designing AI instructions in public health

The Pan American Health Organization (PAHO) has launched a new guide providing practical advice on how to create Artificial Intelligence (AI) prompts that generate reliable, relevant, and culturally appropriate content across diverse contexts.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Prerna launches India's first MicroRNA based blood test for breast cancer screening

Precision RNA Biotech (Prerna), a healthcare startup from Hyderabad, India has announced the launch of Cantel, India's first microRNA-based blood test for breast cancer screening.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr

India-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Sumitomo, Novo Nordisk to co-promote obesity drug Wegovy in Japan

Sumitomo Pharma and Novo Nordisk Pharma have entered into a co-promotion agreement in Japan for Wegovy Subcutaneous Injection, a once-weekly subcutaneous injection formulation of GLP-1 receptor agonist indicated for the treatment of obesity disease.

time to read

1 min

BioSpectrum Asia Nov 2025

Translate

Share

-
+

Change font size